Importantly, they also found that HI-511, a dual-target inhibitor against both AURKB and BRAF V600E, suppresses both drug-sensitive and -resistant melanoma development by inducing apoptosis and mediating the inhibition of the BRAF/MEK/ERKs and PI3K-AKT signaling pathways. The gene discussed is AKT1; the disease is melanoma.